TOPLINE:
Fecal immunochemical test (FIT) screening reduces colorectal cancer (CRC) mortality by 33% overall, with a notable 42% reduction in deaths from left colon and rectal cancers, new data show.
METHODOLOGY:
- In the United States, annual FIT screening is recommended among average-risk adults to reduce the risk for death from CRC, but evidence on its effectiveness is limited.
- Researchers performed a nested case-control study within two large, demographically diverse health systems with long-standing programs of mailing FITs to promote CRC screening efforts.
- They compared 1103 adults who had died of CRC between 2011 and 2017 (cases) with 9608 matched, randomly selected people who were alive and free of CRC (controls).
- Analyses focused on FIT screening completed within 5 years before CRC diagnosis for cases or the corresponding date for controls.
- The primary outcome measured was CRC death overall and by tumor location; secondary analyses assessed CRC death by race and ethnicity.
TAKEAWAY:
- In regression analysis, completing one or more FIT screenings was associated with a 33% lower risk for CRC death overall.
- There was a 42% lower risk for death from left colon and rectum cancers but no significant reduction in mortality from right colon cancers.
- The benefits of FIT screening were observed across racial and ethnic groups, with significant mortality reductions of 63% in non-Hispanic Asian, 42% in non-Hispanic Black, and 29% in non-Hispanic White individuals.
IN PRACTICE:
“The findings support the use of strategies for coordinated and equitable large-scale population-based delivery of FIT screening with follow-up of abnormal screening results to help avert preventable premature CRC deaths,” the authors wrote.
SOURCE:
The study, with first author Chyke A. Doubeni, MD, MPH, Center for Health Equity, The Ohio State University Wexner Medical Center, Columbus, Ohio, was published online in JAMA Network Open.
LIMITATIONS:
Almost one half of study subjects had completed two or more FITs, but the case-control design was not suitable for assessing the impact of repeated screening. The study was conducted prior to the US Preventive Services Task Force recommendation to start screening at age 45 years, so the findings may not directly apply to adults aged 45-49 years.
DISCLOSURES:
The study was funded by the National Cancer Institute. Doubeni reported receiving royalties from UpToDate, and additional authors reported receiving grants outside the submitted work. No other disclosures were reported.
